Mersana to Participate in Four Upcoming Conferences

March 29, 2013

Mersana Therapeutics, a biopharmaceutical company developing its Fleximer® antibody-drug conjugate (ADC) platform and pipeline of small molecule Fleximer conjugates, today announced its participation in four upcoming conferences:

Michael A. Metzger, EVP and Chief Operating Officer, will participate in the panel “Small Biotech: How to Partner Smartly” at the Boston Biotech Business Development Conference on Wednesday, April 3, 2013, at 9:00 a.m. at the Four Seasons Hotel in Boston.

Timothy B. Lowinger, Ph.D., Chief Scientific Officer, will present a poster in the Experimental and Molecular Therapeutics 28 session at the 2013 Annual Meeting of the American Association for Cancer Research (AACR) taking place April 6 - 10, 2013, at the Walter E. Washington Convention Center in Washington, D.C. Abstract #4331, “Advantages of polyacetal polymer-based antibody drug conjugates employing cysteine bioconjugation,” will be presented on Tuesday, April 9, 2013, from 1:00 p.m. to 5:00 p.m. in Hall A-C, Poster Section 36.

Michael A. Metzger will give a company presentation with a corporate overview at the 2013 BIO International Convention being held April 22 - 25, 2013, at McCormick Place in Chicago.

Peter Park, Ph.D., Vice President, Biology, and Timothy B. Lowinger, Ph.D., will be speaking at Antibody-Drug Conjugates at PEGS: The Essential Protein Engineering Summit at the Seaport World Trade Center in Boston. Dr. Park, Chair of Antibody-Drug Conjugates at the Summit, will deliver the Chairperson’s Remarks at 1:30 p.m. on Thursday, May 2, 2013, and Dr. Lowinger will present “Next Generation ADCs: Enabling New Payload Mechanisms and Alternative Targeting Moieties” on Friday, May 3, 2013 at 1:40 p.m.

About Mersana

Mersana engineers novel drug conjugates that maximize the potential of new and established therapeutic classes. Utilizing its proprietary conjugation technology, which is comprised of the Fleximer® polymer and a broad array of customizable linker chemistries, Mersana is developing its next-generation antibody-drug conjugate (ADC) platform with superior properties not found with other ADC technologies. Mersana is currently working with a number of top Pharma companies to develop next generation Fleximer-ADCs and most recently announced a $270 million collaboration with Endo Pharmaceuticals in March, 2012. The company is also advancing its own pipeline of next-generation drugs with best-in-class potential to address unmet needs and improve patient outcomes in multiple oncology indications. 

Media Contact

 MacDougall Biomedical Communications
 Kari Watson
 781-235-3060
 kwatson@macbiocom.com